JAMA Oncology, van Roessel et al found that adjuvant chemotherapy after pancreatic cancer resection and neoadjuvant FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) was associated with an improvement in overall survival. The benefit was limited to patients with node-positive disease.]]> Article Cancer Cell. Among hospitalized patients infected with COVID-19, those with hematologic malignancies who had recently been treated for cancer had the highest levels of SARS-CoV-2.]]> Article The ASCO Post spoke with two ­Latinx oncologists whose life experiences informed their determination to spread awareness of the challenges faced by undocumented patients with cancer.]]> Article Clinical Cancer Research. However, the use of proton pump inhibitors did not impact overall or progression-free survival in patients treated with chemotherapy.]]> Article Journal of Clinical Oncology, Hong et al found that mandatory twice-weekly evaluations reduced the need for unplanned acute care visits among patients undergoing outpatient radiotherapy or chemoradiation who were identified as being at high risk for such visits by a machine-learning algorithm.]]> Article BRCA-Mutated, HER2-Negative Advanced Breast Cancer]]> The ASCO Post Podcast, we'll discuss the efficacy of a triplet combination therapy in BRCA-mutated, HER2-negative advanced breast cancer. Then, we'll move on to a report that detailed multiorgan immunotherapy-related adverse events in patients treated with atezolizumab. Last, we'll review the FDA's approval of the RET-targeted therapy pralsetinib in patients with metastatic RET fusion–positive non–small cell lung cancer.]]> Podcast Karim Fizazi, MD, PhD, on prostate cancer: Results from the ARAMIS trial on darolutamide]]> Karim Fizazi, MD, PhD, on prostate cancer: Results from the ARAMIS trial on darolutamide]]> Video The New England Journal of Medicine, Johann de Bono, MB, ChB, PhD, of the Institute of Cancer Research and Royal Marsden Hospital, London, and colleagues found that olaparib significantly improved progression-free survival vs hormonal therapy in patients with metastatic castration-resistant prostate cancer and alterations in BRCA1, BRCA2, or ATM who had disease progression on a new hormonal therapy.]]> Article Article JAMA Oncology, Dee et al found that radiotherapy initiated at up to 6 months after the start of ADT was not associated with poorer overall survival vs initiation before ADT in men with prostate cancer. The investigators observed that these findings suggest that delay of radiotherapy constitutes an option in the setting of treatment during the COVID-19 pandemic.]]> Article BRCA Alterations]]> Journal of Clinical Oncology by Abida et al, the phase II TRITON2 trial has shown that the PARP inhibitor rucaparib produces durable responses in patients with metastatic castration-resistant prostate cancer with deleterious BRCA1 or BRCA2 alterations. The trial supported the May 2020 accelerated approval of rucaparib in this setting.]]> Article OPDIVO_HCP_Branded_Static_728x90_1506US1602315-03-01]]> ]]> TAP AKI]]>

Attention Advanced Practitioners in Oncology: Early Bird Registration for JADPRO Live Virtual 2020 Now Through September 24

The 8th Annual JADPRO Live meeting will be held virtually from October 15 through November 6. Earn up to 16 CE/CME credits and join in on live Q&A, networking opportunities, and engaging activities.

Register by September 24. Visit